The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa

Arooma Maryam, Sundeep Chaitanya Vedithi, Rana Rehan Khalid, Ali F. Alsulami, Pedro Henrique Monteiro Torres, Abdul Rauf Siddiqi, Tom L. BlundellComputational 2019 · DOI

TL;DR

This study tackles the challenge of understanding how specific mutations in human cGMP phosphodiesterase 6 (PDE6) contribute to cancer and retinitis pigmentosa. By computationally modeling the PDE6 heterodimer and analyzing the effects of known and simulated mutations, the researchers provide structural insights into how these genetic alterations can disrupt protein stability and function, potentially linking them to disease phenotypes.

What Problem Does This Paper Address?

The cGMP signaling pathway is crucial for various cellular functions, and phosphodiesterase 6 (PDE6) plays a key role in regulating intracellular cGMP levels. Aberrant PDE6 activity, often due to somatic mutations, has been linked to serious conditions like cancer and retinitis pigmentosa. However, a detailed understanding of the structural and mechanistic basis for how these mutations lead to disease has been lacking, partly due to the difficulty in obtaining experimental structural data for the full human PDE6 complex. This paper aims to bridge this gap by using computational methods to model the PDE6 structure and predict the functional consequences of specific mutations.

Methods

The researchers employed a multi-pronged computational approach:

  • Homology Modeling: They built a 3D comparative model of the human PDE6αβ heterodimer using existing crystal structures of related PDE enzymes (PDE5 and PDE6C for GAF domains, PDE5 for catalytic domains) and a novel method to assemble these domains.
  • In Silico Mutation Analysis:
    • Known Mutations: They used established tools like mCSM, SDM, and DUET to predict the change in Gibbs free energy (ΔΔG) of folding for experimentally identified mutations associated with cancer and retinitis pigmentosa. They also used mCSM-PPI to assess impacts on protein-protein interfaces and mCSM-NA for cGMP binding.
  • Saturation Mutagenesis: To explore potential effects more broadly, they performed computational saturation mutagenesis on residues at the dimer interface and within the cGMP-binding sites of the Gaf-A and catalytic domains.
  • Interatomic Interaction Analysis: The Intermezzo program was used to visualize and analyze specific changes in non-covalent interactions (hydrogen bonds, van der Waals forces, π-π stacking) between mutated residues, cGMP, and surrounding protein components.

Datasets

  • Protein Sequences: Amino acid sequences for human PDE6α and PDE6β chains were retrieved from UniProt.
  • Known PDE6 Mutations: Experimentally identified missense mutations in PDE6A and PDE6B genes were collected from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Additionally, mutations associated with retinitis pigmentosa were also incorporated.

Key Insights and Ideas

  • PDE6 Heterodimer Structure: The computational model reveals that the PDE6αβ heterodimer is likely organized by two long α-helices, forming a pseudo two-fold axis. Each subunit contains two N-terminal Gaf domains (Gaf-A and Gaf-B) and a C-terminal catalytic domain, with the Gaf domains positioned to allosterically influence catalytic activity.
  • Mutation Impact on Stability: A significant proportion of mutations, particularly in the α-chain, were predicted to be destabilizing, with many showing mild effects but a notable subset exhibiting high destabilization. This suggests that even subtle changes can compromise the protein's structural integrity.
  • cGMP Binding Disruption: Several mutations, especially in the Gaf-A and catalytic domains, were predicted to significantly destabilize cGMP binding. This is a critical finding, as impaired cGMP binding directly affects the enzyme's ability to regulate cGMP levels.
  • Dimer Interface Vulnerability: Mutations at the dimer interface were also found to be destabilizing, indicating that the integrity of the PDE6αβ complex is sensitive to alterations in these regions. This could impact the overall function and assembly of the enzyme.
  • Overlap between Cancer and Retinitis Pigmentosa Mutations: The study highlights that some mutations are implicated in both cancer and retinitis pigmentosa, suggesting shared underlying molecular mechanisms or a common pathway affected by PDE6 dysfunction.

Key Results

  • Model Validation: The homology model of PDE6αβ showed good quality with high percentages of residues in favorable Ramachandran regions.
  • Mutation Prediction:
    • For the α-chain, mCSM predicted 97.5% of mutations as destabilizing, with 12% being highly destabilizing. SDM predicted 5% as highly destabilizing, and DUET predicted 6% as highly destabilizing.
  • For the β-chain, mCSM predicted 91% of mutations as destabilizing, with 6% being highly destabilizing. SDM predicted 8% as highly destabilizing, and DUET predicted 10% as highly destabilizing.
  • Specific mutations like R93L, V141M, and F162L in the Gaf-A domain, D600N, F742L, and F776L in the catalytic domain, and F426A, F248G, and F424N at the dimer interface were identified as potentially highly destabilizing.
  • D600N Mutation: This mutation, found in both cancer and retinitis pigmentosa, was predicted to be highly destabilizing to cGMP binding and metal ion binding in the catalytic pocket.
  • F426A Mutation: This mutation at the dimer interface was predicted to be highly destabilizing, potentially disrupting the heterodimer's structural integrity.

Limitations and Future Work

  • Computational Nature: The study relies heavily on computational predictions. While validated tools were used, experimental validation of the predicted structural and functional impacts of these mutations is crucial.
  • Model Resolution: While a full heterodimer model was constructed, it was based on assembling individual domain models, and the overall resolution might not capture all fine-grained structural details.
  • Experimental Challenges: The authors acknowledge the difficulty in obtaining experimental structures of the active human PDE6, which necessitates the use of computational approaches.
  • Future Directions: The study lays the groundwork for future experimental investigations. Prioritizing mutations for experimental study based on their predicted destabilizing effects on structure, cGMP binding, and dimer interface is a key recommendation. Further research could focus on elucidating the precise molecular mechanisms by which these mutations lead to the observed disease phenotypes.

Summary updated

Abstract

In the cyclic guanosine monophosphate (cGMP) signaling pathway, phosphodiesterase 6 (PDE6) maintains a critical balance of the intracellular concentration of cGMP by catalyzing it to 5' guanosine monophosphate (5'-GMP). To gain insight into the mechanistic impacts of the PDE6 somatic mutations that are implicated in cancer and retinitis pigmentosa, we first defined the structure and organization of the human PDE6 heterodimer using computational comparative modelling. Each subunit of PDE6αβ possesses three domains connected through long α-helices. The heterodimer model indicates that the two chains are likely related by a pseudo two-fold axis. The N-terminal region of each subunit is comprised of two allosteric cGMP-binding domains (Gaf-A & Gaf-B), oriented in the same way and interacting with the catalytic domain present at the C-terminal in a way that would allow the allosteric cGMP-binding domains to influence catalytic activity. Subsequently, we applied an integrated knowledge-driven in silico mutation analysis approach to understand the structural and functional implications of experimentally identified mutations that cause various cancers and retinitis pigmentosa, as well as computational saturation mutagenesis of the dimer interface and cGMP-binding residues of both Gaf-A, and the catalytic domains. We studied the impact of mutations on the stability of PDE6αβ structure, subunit-interfaces and Gaf-cGMP interactions. Further, we discussed the changes in interatomic interactions of mutations that are destabilizing in Gaf-A (R93L, V141 M, F162 L), catalytic domain (D600N, F742 L, F776 L) and at the dimer interface (F426A, F248G, F424 N). This study establishes a possible link of change in PDE6αβ structural stability to the experimentally observed disease phenotypes.
BibTeX
@inproceedings{maryam2019molecular,
  author = {Arooma Maryam and Sundeep Chaitanya Vedithi and Rana Rehan Khalid and Ali F. Alsulami and Pedro Henrique Monteiro Torres and Abdul Rauf Siddiqi and Tom L. Blundell},
  title = {{The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa}},
  booktitle = {Computational},
  year = {2019},
  doi = {10.1016/j.csbj.2019.03.004},
}
Figure